NextCure Valuation
| NXTC Stock | USD 0.50 0 0.60% |
NextCure is overvalued. NextCure secures a last-minute Real Value of $0.43 per share. The latest price of the firm is $0.49700001. Our model forecasts the value of NextCure from analyzing the firm fundamentals such as Return On Equity of -0.64, shares owned by insiders of 8.91 %, and Current Valuation of (37 M) as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting NextCure's valuation include:
Price Book 0.2496 | Enterprise Value | Enterprise Value Ebitda 0.5081 | Price Sales 9.5227 | Enterprise Value Revenue 1.623 |
Overvalued
Today
Please note that NextCure's price fluctuation is out of control at this time. Calculation of the real value of NextCure is based on 3 months time horizon. Increasing NextCure's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since NextCure is currently traded on the exchange, buyers and sellers on that exchange determine the market value of NextCure Stock. However, NextCure's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.5 | Real 0.43 | Target 3.0 | Hype 0.5 | Naive 0.47 |
The real value of NextCure Stock, also known as its intrinsic value, is the underlying worth of NextCure Company, which is reflected in its stock price. It is based on NextCure's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of NextCure's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of NextCure helps investors to forecast how NextCure stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of NextCure more accurately as focusing exclusively on NextCure's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use NextCure's intrinsic value based on its ongoing forecasts of NextCure's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against NextCure's closest peers. If more than one evaluation category is relevant for NextCure we suggest using both methods to arrive at a better estimate.
NextCure Cash |
|
NextCure Valuation Trend
Comparing NextCure's enterprise value against its market capitalization is a good way to estimate the value of NextCure uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
NextCure Total Value Analysis
NextCure is now anticipated to have valuation of (37 M) with market capitalization of 13.94 M, debt of 5.95 M, and cash on hands of 185.49 M. The negative valuation of NextCure may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the NextCure fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(37 M) | 13.94 M | 5.95 M | 185.49 M |
NextCure Asset Utilization
One of the ways to look at asset utilization of NextCure is to check how much profit was generated for every dollar of assets it reports. NextCure secures a negative usage of assets of -0.36 %, losing $0.003639 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of NextCure shows how discouraging it operates for each dollar spent on its assets.NextCure Ownership Allocation
NextCure maintains a total of 28.05 Million outstanding shares. 30% of NextCure outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.NextCure Profitability Analysis
Net Loss for the year was (55.65 M) with loss before overhead, payroll, taxes, and interest of (54.2 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates NextCure's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in NextCure and how it compares across the competition.
About NextCure Valuation
The stock valuation mechanism determines NextCure's current worth on a weekly basis. Our valuation model uses a comparative analysis of NextCure. We calculate exposure to NextCure's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of NextCure's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -3.3 M | -3.1 M | |
| Pretax Profit Margin | (1.47) | (1.55) | |
| Operating Profit Margin | (1.66) | (1.74) | |
| Net Loss | (1.33) | (1.40) | |
| Gross Profit Margin | 0.90 | 0.80 |
NextCure Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 28 M |
NextCure Current Valuation Indicators
Valuation refers to the process of determining the present value of NextCure and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value NextCure we look at many different elements of the entity such as NextCure's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as NextCure, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use NextCure's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes NextCure's worth.Complementary Tools for NextCure Stock analysis
When running NextCure's price analysis, check to measure NextCure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NextCure is operating at the current time. Most of NextCure's value examination focuses on studying past and present price action to predict the probability of NextCure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NextCure's price. Additionally, you may evaluate how the addition of NextCure to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |